Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Linerixibat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 known ✓ | Q12908 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Linerixibat SCHEMBL2579144 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| Linerixibat SCHEMBL2586025 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| Linerixibat SCHEMBL2584943 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL26226892 | 0.97 | SLC10A2 (0.94) | SLC10A2 | |
| SCHEMBL22360124 | 0.97 | SLC10A2 (0.94) | SLC10A2 | |
| SCHEMBL2591812 | 0.97 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL2590845 | 0.95 | SLC10A2 (0.90) | SLC10A2 | |
| SCHEMBL2592666 | 0.95 | SLC10A2 (0.90) | SLC10A2 | |
| SCHEMBL2590143 | 0.95 | SLC10A2 (0.90) | SLC10A2 | |
| SCHEMBL12176709 | 0.94 | SLC10A2 (1.00) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116745289-A | Agonists of free fatty acid receptor 1 and their use in diseases associated with said receptor | 奥洛治疗有限公司 | 2023-09-12 | — | — | CN | claimed |
| WO-2025078973-A1 | SOLID STATE FORMS OF LINERIXIBAT AND PROCESS FOR PREPARATION THEREOF | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2025-04-17 | — | — | WO | disclosed |
| EP-4426428-A1 | TREATMENT WITH ILEAL BILE ACID TRANSPORTER (IBAT) INHIBITORS FOR INCREASED EVENT-FREE SURVIVAL (EFS) | Mirum Pharmaceuticals, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-4422632-A1 | APICAL SODIUM-DEPENDENT TRANSPORTER INHIBITOR COMPOSITIONS | Mirum Pharmaceuticals, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4422631-A1 | METHODS OF DOSING OF APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITORS (ASBTIS) | Mirum Pharmaceuticals, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118159270-A | Apical sodium-dependent transporter inhibitor compositions | 米鲁姆制药公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118139623-A | Methods of administering apical sodium-dependent cholic acid transporter inhibitors (ASBTIs) | 米鲁姆制药公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-116964041-A | Forms of LINERIXIBAT | 葛兰素史克知识产权第二有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116745289-A | Agonists of free fatty acid receptor 1 and their use in diseases associated with said receptor | 奥洛治疗有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116490191-A | Method for treating cholestatic pruritus | 葛兰素史克知识产权第二有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-109415329-B | Synthesis method | 葛兰素史克知识产权第二有限公司 | 2023-05-12 | — | — | CN | disclosed |
| WO-2023081370-A1 | TREATMENT WITH ILEAL BILE ACID TRANSPORTER (IBAT) INHIBITORS FOR INCREASED EVENT-FREE SURVIVAL (EFS) | MIRUM PHARMACEUTICALS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023076260-A1 | APICAL SODIUM-DEPENDENT TRANSPORTER INHIBITOR COMPOSITIONS | MIRUM PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076243-A1 | METHODS OF DOSING OF APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITORS (ASBTIs) | MIRUM PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230138455-A1 | METHODS OF DOSING OF APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITORS (ASBTIs) | MIRUM PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| CN-116042742-A | Synthesis method | 葛兰素史克知识产权第二有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-114096268-A | Methods for increasing growth in pediatric subjects with cholestatic liver disease | 米鲁姆制药公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-114072153-A | Methods for treating cholestasis | 米鲁姆制药公司 | 2022-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230138455-A1 | METHODS OF DOSING OF APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITORS (ASBTIs) | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.